

Supplementary Table S1: exact P values by Mann-Whitney test and Chi-squared test

	ALL COVID PATIENTS					MALE					FEMALE							
	Diseased Control	COVID-19 (all)	COVID-19 CT Stage 1	COVID-19 CT Stage 2	COVID-19 CT Stage 3	Diseased Control	COVID-19 (all)	COVID-19 CT Stage 1	COVID-19 CT Stage 2	COVID-19 CT Stage 3	Diseased Control	COVID-19 (all)	COVID-19 CT Stage 1	COVID-19 CT Stage 2	COVID-19 CT Stage 3			
Gender	n	2717	186	46	55	85	n	999	109	29	30	50	n	1718	77	17	25	35
	Male (%)	999	109	29	30	50	Male (%)	36.8	58.6	63.0	54.5	58.8	Female (%)	1718	77	17	25	35
Age (y)	Female (%)	63.2	41.4	37.0	45.5	41.2	Female (%)	63.2	41.4	37.0	45.5	41.2	Female (%)	63.2	41.4	37.0	45.5	41.2
	PS0	68	69	74	71	63	PS0	68	69	74	71	63	PS0	68	71	68	72	66
25(OH)-Vitamin D (ng/ml)	IQR	49-82	52-80	53-82	60-78	50-80	IQR	53-81	53-79	58-81	59-78	52-77	IQR	46-83	65-74	46-83	64-76	49-82
	Min	18	18	18	39	21	Min	18	21	31	40	21	Min	18	18	18	39	22
≥20 (n)	Max	103	94	94	89	93	Max	100	93	93	89	88	Max	103	94	94	83	93
	≥20 (%)	45.2	58.6	52.2	58.2	62.4	≥20 (%)	49.2	67.0	55.2	66.7	74.0	≥20 (%)	42.8	46.8	47.1	48.0	45.7
OPTIMAL ≥30 (n)	<20 (n)	1227	109	24	32	53	<20 (n)	492	73	16	20	37	<20 (n)	735	36	8	12	16
	<20 (%)	44.8	41.4	47.8	41.8	37.6	<20 (%)	50.8	33.0	44.8	33.3	26.0	<20 (%)	57.2	53.2	52.9	52.0	54.3
OPTIMAL ≥30 (%)	≥30 (n)	729	33	12	10	11	≥30 (n)	213	15	7	4	4	≥30 (n)	516	18	5	6	7
	≥30 (%)	26.8	17.7	26.1	18.2	12.9	≥30 (%)	21.3	13.8	24.1	13.3	8.0	≥30 (%)	30.0	23.4	29.4	24.0	20.0
OPTIMAL <30 (n)	<30 (n)	1588	153	34	45	74	<30 (n)	786	94	22	26	46	<30 (n)	1202	59	12	15	28
	<30 (%)	58.2	41.4	52.2	51.8	62.4	<30 (%)	78.7	86.2	75.9	86.7	92.0	<30 (%)	70.0	76.6	70.6	76.0	80.0

statistical differences in median 25(OH)D levels across groups calculated by Mann-Whitney test. Proportions for categorical variables were compared using the chi-squared test

Supplementary methods: detailed CT scanning protocol

All patients were imaged by MDCT using either of the following CT scanners: the GE LightSpeed VCT scanner (1-mm slice thickness), Siemens Somatom AS (1-mm slice thickness) or the GE Optmima 660 scanner (1.25-mm slice thickness). All scans were performed without intravenous contrast with the patient in the supine position during end-inspiration. Only the initial CTs were included; follow-up CTs during the study time window were not analyzed. *Image Viewing and Evaluation* Two cardiothoracic radiologists with 24 and 9 years of experience retrospectively reviewed the CT exams on a PACS workstation (IDS7, Sectra) with multiplanar reconstruction tools. Decision was reached by consensus. For each patient, the chest CT scan was evaluated for the following characteristics: (1) presence of ground-glass opacities (early stage, “**stage 1**”), (2) presence of crazy paving pattern (progressive stage, “**stage 2**”), (3) presence of consolidation (peak stage, “**stage 3**”), (4) number of lobes affected where either ground-glass / consolidative opacities were present, (5) degree of involvement of each lung lobe in addition to overall extent of lung involvement measured by means of a “CT-severity score” as detailed below, (6) presence of a pleural effusion, (7) presence of pericardial effusion, (8) presence of thoracic lymphadenopathy (defined as lymph node size of ≥ 10 mm in short-axis dimension), (10) airways abnormalities (including bronchiectasis, bronchial wall thickening and endoluminal secretions), (11) craniocaudal and anteroposterior distribution of disease (12) presence of underlying lung disease such as emphysema or fibrosis. Each of the five lung lobes was assessed for degree of involvement and classified as none (0%), discrete (<5%), minimal (5 - 25%), mild (26 - 50%), moderate (51 - 75%), or severe (> 75%). No involvement corresponded to a lobe score of 0, discrete to a lobe score of 1, minimal to a lobe score of 2, mild to a lobe score of 3, moderate to a lobe score of 4, and severe to a lobe score of 5. An overall lung “CT-severity score” was reached by summing the five lobe scores (range of possible scores, 0 - 25). CT-severity score was not used in the current study.

The stage was estimated by consensus evaluation of the predominant radiological presentation: ground-glass opacities (early stage, 0-4 days, “stage 1”), (2) presence of crazy paving pattern (progressive stage, 5-8 days, “stage 2”), (3) presence of consolidation (peak stage, 10-13 days, “stage 3”) ¹

Reference

1. Bernheim A, Mei X, Huang M, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. *Radiology*. 2020:200463.